NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary Chapter: 7 - Obstetrics, Gynaecology, and urinary-tract disorders 
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing
07.04.03 Drugs used in urological pain
07.04.03 Alkalinisation of urine
07.04.03 Acidification of urine
07.04.03 Other preparations for urinary disorders

Dapagliflozin
(For Chronic kidney disease)

 
First Choice

Green Recommended for initiation in primary care for patients in line with NICE NG28, NICE TA1075 and NICE TA942 except those cases mentioned below under SpA initiation.

Amber SPA Nephrology specialists to advise (e.g., via Advice and Guidance prior to initiation in Primary Care for the following categories (as there is no data from large randomised controlled trials for these cohorts):

• Kidney transplant recipients

• Polycystic kidney disease

• Lupus nephritis

• ANCA associated vasculitis.

• Kidney disease where patient takes drugs which suppress the immune system

 

Prescribe generically

Entry reviewed: September 2025

BNF BNFc SPC
BLMK ICB SGLT2 inhibitors for treating chronic kidney disease - Primary Care Prescribing Guidance

Budesonide, targeted-release (Kinpeygo®)
(For primary IgA nephropathy)

RED
Restricted Drug Restricted

 4mg modified-release hard capsules

Restricted for use in accordance with NICE TA937 only

 

Entry reviewed: December 2023

BNF BNFc SPC BlueTeq
NICE TA937: Targeted-release budesonide for treating primary IgA nephropathy

Canagliflozin
(For Chronic kidney disease WITH Type 2 diabetes)

 
Formulary

Alternative option for CKD with T2DM only

Green Recommended for initiation in primary care for patients in line with NICE NG28, NICE TA1075 and NICE TA942 except those cases mentioned below under SpA initiation.

Amber SPA Nephrology specialists to advise (e.g., via Advice and Guidance prior to initiation in Primary Care for the following categories (as there is no data from large randomised controlled trials for these cohorts):

• Kidney transplant recipients

• Polycystic kidney disease

• Lupus nephritis

• ANCA associated vasculitis.

• Kidney disease where patient takes drugs which suppress the immune system

Entry reviewed: July 2025

BNF BNFc SPC
BLMK ICB SGLT2 inhibitors for treating chronic kidney disease - Primary Care Prescribing Guidance

Empagliflozin
(For Chronic kidney disease)

 
Formulary

Green Recommended for initiation in primary care for patients in line with NICE NG28, NICE TA1075 and NICE TA942 except those cases mentioned below under SpA initiation.

Amber SPA Nephrology specialists to advise (e.g., via Advice and Guidance prior to initiation in Primary Care for the following categories (as there is no data from large randomised controlled trials for these cohorts):

• Kidney transplant recipients

• Polycystic kidney disease

• Lupus nephritis

• ANCA associated vasculitis.

• Kidney disease where patient takes drugs which suppress the immune system

Entry reviewed: July 2025

 

BNF BNFc SPC
BLMK ICB SGLT2 inhibitors for treating chronic kidney disease - Primary Care Prescribing Guidance

Sparsentan (Filspari®)
(For primary IgA nephropathy)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form required - see link from Formulary Homepage.

To be used in accordance with the following NICE TA(s) only:

 

Entry reviewed: June 2025

BNF BNFc SPC
NICE TA1074: Sparsentan for treating primary IgA nephropathy
Classifications
GREEN
May be initiated in any care setting
Amber SPA
Specialist to advise therapy and provide first 28 days supply, continuation in Primary Care
Amber SPIS
Specialist to initiate and stabilise medicine prior to continuation in Primary Care
SCG
To be prescribed as per Shared Care Guidance. If no SCG in place status reverts to red.
RED
Red medicines are designated as specialist only medicines which should only be prescribed by a specialist, usually within secondary care (either due to the requirement for specialist knowledge, long-term monitoring requirements, or restrictions that mean medicine supplies are only available to hospitals).
DNP
A decision has been made either locally and/or nationally not to routinely commission this preparation. Do not prescribe.
SELF
To be purchased over the counter. May be prescribed for chronic, long term conditions or on admission to hospital if essential.